MINPP1 and hepatocellular carcinoma: Since MINPP1 participates in the glycolytic bypass, which is a component of the glycolysis/gluconeogenesis pathway (Figure S1), it was hypothesized that MINPP1 inhibited the development of HBV-positive HCC through a metabolic mechanism.